XNAS · Diagnostics & Research
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$511.65+1.02%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
52/100
Moderate
Score components
TickerWhale View
Idexx Laboratories scores 52 out of 100 overall, which we rate moderate. Quality & growth is its strongest area and Technical its weakest.
What helps
- Quality & growth
What to watch
- Technical
- Valuation
- Risk
Quality & growth
30%93Strong
- Revenue growth 12.8%
- EPS growth 18.4%
Valuation
25%41Weak
- P/E 35.6
- EV/Sales 9.1
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
#288 by market cap in our coverage · ~11,000 employees · Listed 1991-06-21 · www.idexx.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#86 / 139sector rank by TickerWhale Score
TickerWhale Score 52 vs sector average 55.1 (-3.1)
Revenue growth (industry)Top 37%
Gross margin (industry)Top 24%
Return on equity (industry)Top 12%
P/E (industry)Pricier than 64%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
16/100Weak vs universe
Ranks 16th of 100 covered names on our technical composite — the composite itself scores 27/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 4 sell · 2 neutral of 8 votes
TickerWhale rates IDXX's technical setup weak — 16th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
0 / 9constructive
- vs 200-day-14.4%
- vs 50-day-7.1%
Momentum
Mixed
- RSI (14)38 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength24· trending
- MACD (12,26,9)sell(histogram -1.553)
How the classic verdict is reached
Moving averages (9) agree on sell — 0 buy vs 8 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 3 sell · 2 neutral.
Result — 2 buy vs 4 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)35.6
- P/S (TTM)8.9
- P/B25.2
- EV/EBITDA—
- EV/Sales9.1
- PEG1.94
Profitability & returns
- Gross margin62.5%
- Net margin25.0%
- ROE71.9%
- Debt/Equity0.60
Growth
- Revenue growth (YoY)12.8%
- EPS growth (YoY)18.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $40.6B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXXCurrentIdexx Laboratories | 52 | 27 | 35.6 | — | 25.2 | 9.1 | $511.65 | +1.02% | +12.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.